Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that combined oral contraceptives and spironolactone are effective treatments for adult acne in women, but noted that oral contraceptives increase the risk of venous thromboembolism and require individual risk assessment before use.

This study found that both combined therapy with goserelin and oral contraceptives, and oral contraceptives alone, significantly reduced hair diameter in severe hirsutism without a significant difference between treatments.

This study observed that 100% of cancer patients at Dr. Moewardi Surakarta Hospital receiving carboplatin-paclitaxel chemotherapy experienced grade 2 alopecia as an adverse drug reaction.

This study compared the effectiveness of combined oral contraceptives and antiandrogens for treating women with polycystic ovarian syndrome in late reproductive age.

This systematic review evaluates the effectiveness and safety of various treatments for polycystic ovary syndrome including finasteride, flutamide, and metformin, but does not provide specific new results.

This study developed and tested Bicalutamide-loaded lipid vesicles in dissolving microarray patches for topical application, finding that they effectively deliver Bicalutamide through murine skin while maintaining a favorable safety profile, suggesting potential to improve treatments for androgenetic alopecia.

This study found that a combined oral contraceptive containing ethinyl estradiol and desogestrel appeared effective in temporarily treating ovarian hyperandrogenism in adolescents, with reductions in hormone levels and ovarian volume observed.

This review covers the use of combined oral contraceptives, particularly drospirenone, for managing polycystic ovary syndrome and discusses related metabolic controversies without reporting new clinical results.

In this study, researchers found that bicalutamide was more effective and had a better safety profile than spironolactone for treating female-pattern hair loss in women aged 18 to 50, based on the Sinclair scale and photographic assessments after 24 weeks of treatment.

The birth control pill containing ethinylestradiol and chlormadinone may help treat acne and other skin and hair conditions related to hormones.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study found that treatment with a GnRH agonist and estrogen and progestin replacement significantly improved hirsutism scores and hair growth rates in women with polycystic ovarian disease.

This study found that pregnane derivatives with higher lipophilicity, like compound 9d, had stronger androgen receptor binding and greater antiandrogenic effects in rats, correlating relative binding affinity with log P values.

In this study, researchers demonstrated that in a mouse model, the stimulation of mammary tumor growth due to progesterone is primarily caused by its metabolite, 5αP, not progesterone itself.

Results are not reported in this abstract, which notes that while Janus kinase inhibitors like baricitinib show therapeutic benefits for alopecia areata, the mechanisms and reliable predictors of response remain unclear.

This study found that retinol palmitate treatment in patients with stage Ia non-small-cell lung cancer may reduce cancer relapses, but longer follow-up is needed to confirm its efficacy.

This article reviews the diverse clinical applications of oral contraceptives beyond birth control, suggesting their effectiveness in treating various female health disorders and conditions.

This article discusses the importance of recognizing adverse drug reactions, methods of prevention, and encourages reporting them to the FDA's MedWatch program; it reports no new results.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study describes the molecular conformation and intermolecular interactions in the crystalline structure of the compound C24H31BrO4.

In this retrospective pharmacovigilance study, researchers analyzed over 7,900 adverse event reports related to aromatase inhibitors, identifying common side effects and toxicological mechanisms to highlight potential safety concerns in treating postmenopausal hormone receptor-positive breast cancer.

This study found that both spironolactone with Ovysmen and cyproterone acetate with ethinyloestradiol significantly reduced hair growth in hirsute women, with no difference in effect between treatments.

In this study, lysocellin induced G1 phase arrest in human osteosarcoma cells, but diminished the cytotoxic efficacy of etoposide, while its derivative alopestatin may reduce etoposide-induced alopecia in a rat model.

This study by Moussa et al. reported that bicalutamide may help reduce minoxidil-induced hypertrichosis in women with female pattern hair loss.

This review discusses the potential role of a PADI3 gene variant in central centrifugal cicatricial alopecia among African-American women but reports no new clinical results.

This review discusses non-oral hormonal contraceptives and other exogenous steroid hormones, reporting they are generally safe for temporary use in women without breast cancer, but data are limited.